What Is the EU Pharma Package and Does It Affect You Yet?
If you are a pharmaceutical manufacturer, wholesaler, or distributor operating within or supplying into the European Union, you are likely asking one question right now: does the EU Pharma Package actually change anything for my GMP or GDP operations today? The answer is yes, and sooner than most organisations have been told.
EU co-legislators have reached a provisional agreement to modernise the pharmaceutical framework for the first time in two decades. The reform aims to make medicines more available, affordable, and innovative, while strengthening Europe’s competitiveness and security of supply. The final texts have now been officially published, with the European Parliament’s SANT Committee voting on both texts on 18 March 2026, followed by final approval, translation, and publication in the Official Journal.
This blog breaks down exactly what has changed, what is coming next, and the specific actions GMP manufacturers and GDP distributors need to take right now.
The Timeline Most Operators Are Getting Wrong
In all public communications to date, the message was consistent: the new pharmaceutical legislation would only enter into force 18 to 36 months after publication in the Official Journal. This statement was widely repeated in presentations, stakeholder briefings, and conference discussions.
However, that is not the full picture. Internal EU coordination indicates that parts of the new EU Pharmaceutical Package will become applicable earlier than publicly communicated. The Union List of Critical Medicines is expected to apply from the date of entry into force, with further provisions on security of supply to follow six months later.
In practice, the staggered model works like this:
- Day 0 (entry into force): The Union List of Critical Medicines becomes immediately applicable
- Six months after entry into force: Chapter X on Availability and Security of Supply becomes applicable
- 18 to 36 months: The broader legislative framework phases in for general compliance
This means organisations handling critical medicines or supply-sensitive product categories face live obligations now, not at the end of a multi-year runway.
What Has Changed for GMP Manufacturers
Supply Security Is Now a QMS Obligation
The new framework introduces formal requirements around supply continuity that must be embedded inside your Quality Management System. This is not just a commercial or logistics issue anymore. It is a quality governance issue that inspectors will look for.
Key actions for manufacturers:
- Review and update risk management SOPs to include supply continuity scenarios
- Embed shortage risk as a structured element within your pharmaceutical quality system
- Ensure CAPA workflows are equipped to handle shortage-related deviation investigations
- Conduct a gap assessment against the Union List of Critical Medicines to identify affected products
Outsourced Activities Face Tighter Oversight
The Pharma Package reinforces the expectation that manufacturers maintain active and demonstrable oversight of all outsourced manufacturing and quality activities. Third-party oversight is now a front-line inspection target, not a back-office function.
What inspectors will look for:
- Documented supplier qualification records
- Evidence of regular vendor audits and review cycles
- Active contract manufacturing organisation (CMO) governance
- Written assessments of contract suitability aligned with EU GMP Chapter 7
Qualified Person Accountability Is Strengthened
The new directive increases the legal and operational accountability attached to QP certification decisions. Robust QP support is now essential, including:
- Clear and documented batch release procedures
- Well-maintained annual product quality reviews
- Documented quality oversight records that are current and inspection-ready
What Has Changed for GDP Operators
Wholesaler Sourcing Rules Are Tightening
The new directive will require wholesalers to source medicinal products exclusively from suppliers holding a valid Wholesale Distribution Authorisation (WDA) within the EU or a valid manufacturing authorisation. This closes a gap around fiscal import models and legal title transfer arrangements used by some distribution networks.
GDP operators should be reviewing:
- Current sourcing arrangements and affiliate supply models
- Supplier authorisation status for all active supply relationships
- Contract terms with third-party logistics providers
Supply Chain Traceability Expectations Are Higher
The Pharma Package places renewed emphasis on end-to-end traceability across the distribution chain. GDP-licensed organisations should expect greater scrutiny on:
- Batch-level documentation completeness and audit trail integrity
- Temperature monitoring records and excursion management processes
- Supplier verification and due diligence records
- Return and recall documentation aligned with the new framework
Pandemic Certificate Extensions Are Over
The European Medicines Agency clarified that a blanket extension of GDP certificates will no longer be granted. This decision is based on the fact that national authorities have resumed regular on-site inspections and that alternative approaches such as remote assessments are now available. Distributors who relied on extended certificates must ensure full current-baseline compliance before the next inspection cycle.
What GMP and GDP Operators Should Do Right Now
Do not wait for the full legislative text to be finalised before acting. The staggered implementation model means some obligations are live today. The following steps should be initiated immediately:
- Check the Union List of Critical Medicines and confirm whether any of your products are included
- Commission a gap analysis of your QMS against supply security and third-party oversight requirements
- Review all SOPs governing GDP logistics, batch release, CAPA, and outsourced activities
- If your last GDP audit was conducted under pandemic flexibility arrangements, commission a fresh baseline audit
- Update GMP and GDP training content to reflect the new legislative context
- Assign a responsible person within your quality team to formally track the Official Journal publication date and the six-month supply security trigger
- Review all CMO and third-party contracts for compliance with updated outsourcing governance expectations
How Quality and Vigilance Ltd Can Help
At Quality and Vigilance Ltd, we provide specialist GMP and GDP compliance support to help pharmaceutical manufacturers and distributors prepare for and respond to regulatory change. Our services directly relevant to the EU Pharma Package include:
- GMP audit services and gap assessments for manufacturers
- GDP compliance audits for wholesalers and distributors
- QMS design and optimisation to embed supply risk governance
- CAPA management and root-cause analysis support
- Supplier qualification and vendor audit programmes
- SOP development and controlled document review
- GMP and GDP training for quality teams and operational staff
Get in touch with our team to discuss how the EU Pharma Package affects your specific operations and what steps you need to take now.